uniQure vs Stoke Therapeutics
QURE and STOK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How QURE and STOK compare
uniQure and Stoke Therapeutics are about the same size, with market caps of $1.7B and $1.7B.
uniQure grew revenue faster over the last twelve months (28.0% versus −86.2% for Stoke Therapeutics).
Stoke Therapeutics keeps more of each dollar of sales as profit, with a net margin of −754% compared with −1155% at uniQure.
Stoke Therapeutics scores higher on the StockData Score (6 against 4 for uniQure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | QURE | STOK |
|---|---|---|
| Size and price | ||
| Market cap | $1.7B | $1.7B |
| Share price | $23.81 | $26.68 |
| Change, 1 year | −20.9% | 6.2% |
| Change, 5 years | −19.7% | −4.0% |
| Beta (5Y) | 1.67 | 1.62 |
| Employees | 221 | 170 |
| StockData Score | ||
| Total score | 4 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 0 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 81.9× | 62.4× (better) |
| P/B | 5.6× | 5.0× (better) |
| FCF yield | −11.7% | −10.5% (better) |
| Fair value | $5.95 | $9.57 |
| Margin of safety | −300% | −179% (better) |
| Growth | ||
| Revenue growth (TTM) | 28.0% (better) | −86.2% |
| Revenue growth, 5Y average | −15.6% | – |
| Net income growth (TTM) | – | −496% |
| EPS growth (TTM) | – | −501% |
| Profitability | ||
| Gross margin | 93.9% | – |
| Operating margin | −1002% | −810% (better) |
| Net margin | −1155% | −754% (better) |
| FCF margin | −957% | −655% (better) |
| Return on equity | −89.0% | −61.1% (better) |
| Return on invested capital | – | −252% |
| Financial health | ||
| Debt / equity | 0.17 (better) | 0.00 |
| Interest coverage | −3.5× (better) | −4856.0× |
| Current ratio | 11.52 (better) | 7.69 |
| Altman Z-score | −0.62 | 18.22 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 96.0% | 120% |
| Held by insiders | 2.1% | 41.6% |
| Insider net buying, 12 months | −$20.2M | −$6.7M (better) |
| Short interest, % of float | 12.5% | 28.5% |
Go deeper
- QURE stock overview
- QURE income statement
- QURE valuation and score
- STOK stock overview
- STOK income statement
- STOK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.